A5090069473- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Cancer, Hypoxia, and Metabolism
- Renal cell carcinoma treatment
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Angiogenesis and VEGF in Cancer
- Neuroendocrine Tumor Research Advances
- Brain Metastases and Treatment
- Occupational and environmental lung diseases
- Neuroblastoma Research and Treatments
- Melanoma and MAPK Pathways
- Cancer therapeutics and mechanisms
- Renal and related cancers
- Cancer Research and Treatments
- Computational Drug Discovery Methods
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Muscle and Compartmental Disorders
- PI3K/AKT/mTOR signaling in cancer
HealthPartners
2017-2024
Mayo Clinic
2024
Mayo Clinic in Arizona
2023-2024
WinnMed
2024
Metro-Minnesota Community Oncology Research Consortium
2021-2024
Regions Hospital
2019-2024
University of Minnesota
2010-2023
GTx (United States)
2014-2023
Vanquish Oncology (United States)
2022-2023
Cancer Research Center
2020-2021
This study demonstrates that a CD34–, vascular endothelial cadherin– (VE-cadherin–), AC133+, and fetal liver kinase+ (Flk1+) multipotent adult progenitor cell (MAPC) copurifies with mesenchymal stem cells from postnatal human bone marrow (BM) is for angioblasts. In vitro, MAPCs cultured VEGF differentiate into CD34+, VE-cadherin+, Flk1+ — phenotype would be expected They subsequently express markers, function in vitro as mature cells, contribute to neoangiogenesis vivo during tumor...
This study demonstrates that a CD34–, vascular endothelial cadherin– (VE-cadherin–), AC133+, and fetal liver kinase+ (Flk1+) multipotent adult progenitor cell (MAPC) copurifies with mesenchymal stem cells from postnatal human bone marrow (BM) is for angioblasts. In vitro, MAPCs cultured VEGF differentiate into CD34+, VE-cadherin+, Flk1+ — phenotype would be expected They subsequently express markers, function in vitro as mature cells, contribute to neoangiogenesis vivo during tumor...
AGS-003 is an autologous immunotherapy prepared from fully matured and optimized monocyte-derived dendritic cells, which are co-electroporated with amplified tumor RNA plus synthetic CD40L RNA. was evaluated in combination sunitinib open label phase 2 study intermediate poor risk, treatment naïve patients metastatic clear cell renal carcinoma (mRCC).Twenty-one risk were treated continuously (4 weeks on, off per 6 week cycle). After completion of the first cycle sunitinib, every 3 for 5...
Bronchiolitis obliterans (BrOb), a late complication of bone marrow transplantation (BMT), is associated with chronic graft-versus-host disease (GVHD) and frequently fatal. To identify the risk factors BrOb, affecting survival, treatment outcomes, causes death patients we retrospectively analyzed 2859 BMT recipients. No cases BrOb occurred among 1070 autologous Among 1789 allogeneic recipients, identified 47 BrOb. In multivariate analysis, older recipients or donors acute GVHD were...
Sunitinib and sorafenib are small-molecule tyrosine kinase inhibitors (TKI) with antitumor activity in advanced renal cell carcinoma. A retrospective study was conducted to assess the response of carcinoma sequential treatment these two agents.Tumor evaluated by using Response Evaluation Criteria In Solid Tumors (RECIST) criteria patients failing first-line therapy either sunitinib or subsequently receiving second-line other TKI agent.Twenty-nine received followed (Group A), 20 B). drugs...
Brain metastases are a common cause of death in stage IV metastatic melanoma. Dabrafenib is BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 glutamic acid substitution (BRAF<sup>V600E</sup>), which commonly found Clinical trials with dabrafenib have shown encouraging results; however, central nervous system distribution remains unknown. Thus, objective current study was evaluate brain mice, and see whether...
Abstract Purpose: Recent advances in the understanding of innate immunity suggest that an orchestrated sequence events is required to elicit a productive immune response against cancer. We studied systemic administration Toll-like receptor 7 agonist 852A, small-molecule imidazoquinoline, patients with advanced Preclinical studies showed 852A stimulates plasmacytoid dendritic cells produce multiple cytokines, such as IFN-α, interleukin-1 antagonist, and IFN-inducible protein-10. Our goal was...
Inhibiting src kinases (non-receptor tyrosine kinase signaling intermediates) reduces melanoma cell proliferation and invasion. Dasatinib inhibits c-kit, PDGFβR, EPHA2 c-src, c-Yes, Lck, Fyn. A phase 2 trial of dasatinib in was conducted to assess response rate (RR), progression-free survival (PFS), toxicity.Adults with stage 3/4 chemotherapy-naïve unresectable were eligible. initially administered at 100 mg twice daily continuously 17 patients. Due toxicity, the starting dosage decreased 70...
Amrubicin is a synthetic anthracycline with potent topoisomerase II inhibition. This phase study was conducted to confirm safety and activity of amrubicin in the treatment refractory small-cell lung cancer (SCLC).Patients SCLC (either progressive disease as best response or progression within 90 days first-line therapy) received (40 mg/m(2)/d for 3 every 21 days). The primary end point overall rate (ORR); secondary points included progression-free survival (PFS), (OS), change left...
Abstract Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report results phase 2 PrE0505 trial ( NCT02899195 ) anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control cisplatin pemetrexed chemotherapy; secondary exploratory endpoints...
Objective To evaluate the frequency, risk factors, and clinical presentation of bisphosphonate (BP)-related osteonecrosis jaw (BRONJ). Study Design We performed a retrospective analysis 576 patients with cancer treated intravenous pamidronate and/or zoledronate between January, 2003 December, 2007 at University Minnesota Masonic Cancer Center Park Nicollet Institute. Results Eighteen identified (3.1%) developed BRONJ including 8 190 (4.2%) breast cancer, 6 83 (7.2%) multiple myeloma, 2 84...
The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients with extensive-stage small-cell lung cancer (ES-SCLC).
The vascular endothelial growth factor-A (VEGF-A)-VEGFR2 pathway drives tumor vascularization by activating proangiogenic signaling in cells (ECs). Here, we show that EC-sphingosine-1-phosphate receptor 1 (S1PR1) amplifies VEGFR2-mediated angiogenic to enhance growth. We cancer induce S1PR1 activity ECs, and thereby, conditional deletion of ECs (EC-S1pr1−/− mice) impairs Mechanistically, engages the heterotrimeric G-protein Gi, which VEGF-VEGFR2 due an increase tyrosine kinase c-Abl1....
Abstract Purpose: ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor. We evaluated the safety and preliminary efficacy plus pembrolizumab in patients with advanced solid tumors. Patients Methods: This was an open-label, multicenter, Phase 1b/2 study (NCT02880371) performed over September 1, 2016 to October 24, 2019. In 1b dose-escalation, selected tumors received [starting dose 200 mg once daily (QD) orally] [2 mg/kg intravenously (IV) every 3 weeks...
Clarkson disease (monoclonal gammopathy-associated idiopathic systemic capillary leak syndrome, ISCLS) is a rare, relapsing-remitting disorder featuring the abrupt extravasation of fluids and proteins into peripheral tissues, which in turn leads to hypotensive shock, severe hemoconcentration, hypoalbuminemia. Specific leakage factor(s) pathways ISCLS are unknown, there no effective treatment for acute flares. Here we characterize an autonomous vascular endothelial defect that recapitulated...
This study demonstrates that a CD34–, vascular endothelial cadherin– (VE-cadherin–), AC133+, and fetal liver kinase+ (Flk1+) multipotent adult progenitor cell (MAPC) copurifies with mesenchymal stem cells from postnatal human bone marrow (BM) is for angioblasts. In vitro, MAPCs cultured VEGF differentiate into CD34+, VE-cadherin+, Flk1+ — phenotype would be expected They subsequently express markers, function in vitro as mature cells, contribute to neoangiogenesis vivo during tumor...